SCHEMBL3941177

SCHEMBL3941177

O=C1c2ccccc2C(=O)N1C[C@H](O)CNc1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
MAPT P10636 2/20 0.53
RPS6KA3 P51812 1/20 0.49
RPS6KA2 Q15349 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 4/20 0.46
ALOX15 P16050 3/20 0.46
MAPK1 P28482 2/20 0.46
KMT2A Q03164 1/20 0.45
HTT P42858 2/20 0.44
HPGD P15428 3/20 0.44
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29746037 1.00 ALDH1A1 (0.53) ALDH1A1MAPTRPS6KA3RPS6KA2NPC1
SCHEMBL16197764 1.00 ALDH1A1 (0.53) ALDH1A1MAPTRPS6KA3RPS6KA2NPC1
SCHEMBL16204409 0.90 MAPT (0.55) ALDH1A1MAPTRPS6KA2NPC1RAB9A
SCHEMBL28676073 0.89 MAPT (0.54) ALDH1A1MAPTRPS6KA3RPS6KA2NPC1
SCHEMBL18826923 0.89 RPS6KA2 (0.44) ALDH1A1MAPTRPS6KA3RPS6KA2NPC1
SCHEMBL23030168 0.81 HTT (0.49) ALDH1A1MAPTNPC1RAB9AL3MBTL1
SCHEMBL12126890 0.81 HTT (0.49) ALDH1A1MAPTNPC1RAB9AL3MBTL1
SCHEMBL2867969 0.81 HTT (0.49) ALDH1A1MAPTNPC1RAB9AL3MBTL1
SCHEMBL16189751 0.81 NPC1 (0.50) ALDH1A1MAPTNPC1RAB9AL3MBTL1
SCHEMBL15618724 0.81 HTT (0.49) ALDH1A1MAPTNPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US claimed
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2016-04-14 US claimed
EP-2989097-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES Symed Labs Limited (IN) 2016-03-02 EP claimed
WO-2014174522-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2014-10-30 WO claimed
EP-1768967-B1 NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS SYMED LABS LTD (IN) 2009-04-22 EP claimed
US-7429661-B2 Intermediates for linezolid and related compounds SYMED LABS LIMITED (IN) 2008-09-30 US claimed
EP-1768967-A1 NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS Symed Labs Limited (IN) 2007-04-04 EP claimed
US-20060247435-A1 Novel intermediates for linezolid and related compounds HETERO USA, INC. (US) 2006-11-02 US claimed
WO-2006008754-A1 NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS SYMED LABS LIMITED (IN) 2006-01-26 WO claimed
US-9643939-B1 Process for the preparation of linezolid OPTIMUS DRUGS PRIVATE LIMITED (US) 2017-05-09 US disclosed
US-9643939-B1 Process for the preparation of linezolid OPTIMUS DRUGS PRIVATE LIMITED (US) 2017-05-09 US disclosed
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US disclosed
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US disclosed
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US disclosed
WO-2010084514-A2 A PROCESS FOR THE PREPARATION OF (5S)-(N)-[[3-[3-FLUORO-4-(4-MORPHOLINYL) PHENYL]-2-OXO-5-OXAZOLIDINYL] METHYL] ACETAMIDE NEULAND LABORATORIES LTD. (IN) 2010-07-29 WO disclosed
EP-1768967-B1 NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS SYMED LABS LTD (IN) 2009-04-22 EP disclosed
US-7429661-B2 Intermediates for linezolid and related compounds SYMED LABS LIMITED (IN) 2008-09-30 US disclosed
EP-1768967-A1 NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS Symed Labs Limited (IN) 2007-04-04 EP disclosed
US-20060247435-A1 Novel intermediates for linezolid and related compounds HETERO USA, INC. (US) 2006-11-02 US disclosed
WO-2006008754-A1 NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS SYMED LABS LIMITED (IN) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES CYP3A5, SBDS, MLYCD ALDH1A1 610/4885MAPT 2879/4885RPS6KA3 938/4885
US-20060247435-A1 Novel intermediates for linezolid and related compounds HPD, PTMS, HDAC5 ALDH1A1 1903/4885MAPT 1308/4885RPS6KA3 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.